

POSTER PRESENTATION

Open Access

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy

Prashanth Prithviraj¹, Grant McArthur², Victoria Atkinson³, Phillip Parente⁴, Miles Andrews^{1*}, Sagun Parakh¹, Michael Millward⁵, Jonathan Cebon⁶, Oliver Klein¹

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. 4-8 November 2015

Background

Immunotherapy with anti-CTLA-4 and anti-PD-1 antibodies has demonstrated overall survival benefits in patients (pts) with metastatic melanoma (MM) compared to previous standard therapy. Two randomised clinical trials indicate that combined anti-CTLA-4 and anti-PD-1 antibody therapy increases the response rate compared to single agent treatment, but is associated with increased toxicity [1,2]. Both efficacy and toxicity of anti-PD-1 therapy appear independent of prior treatment with the anti-CTLA-4 antibody ipilimumab. To date, only limited evidence exists regarding the efficacy and toxicity of Ipilimumab in pts that have progressed on treatment with an anti-PD-1 agent.

Methods

We retrospectively identified pts with MM who received anti-PD-1 therapy (Nivolumab/Pembrolizumab) and were subsequently treated with ipilimumab. Ipilimumab was administered at a dose of 3mg/kg every three weeks for (up to) four doses and response assessed by CT scan 4-6 weeks after the last dose. Efficacy and toxicity outcomes were determined from clinical records.

Results

The median age was 53 years with all pts having stage IVc disease and 4 pts (33%) with an elevated LDH at commencement of Ipilimumab dosing. The median time between the last dose of anti-PD-1 therapy and the

commencement of Ipilimumab was 8 months (range 2-14 months). After a median follow-up of over 6 months, 1 patient (8%) achieved a partial remission as their best response to anti-PD-1 therapy with an additional 6 (50%) having stable disease. Five patients (42%) received all four doses of Ipilimumab. Two patients (17%) achieved an objective response to ipilimumab with another having prolonged stable disease. Four patients experienced grade 3/4 immune-related adverse events (irAE) including colitis (n=3) and pneumonitis (n=1).

Conclusions

Ipilimumab therapy can induce responses in patients who have failed treatment with an anti-PD-1 antibody. The response rate and clinical benefit rate appears similar compared to outcomes in pts who have not received prior anti-PD-1 antibody therapy. Although cases of severe and/or unusual irAEs such as pneumonitis have been observed, an analysis of a larger patient cohort will be required to test the significance of these observations.

Authors' details

¹Medical Oncology, Austin Health, Heidelberg, Australia. ²Peter MacCallum Cancer Centre, East Melbourne, Australia. ³Princess Alexandra Hospital, Woolloongabba, Australia. ⁴Eastern Health Clinical School, Box Hill Hospital, Box Hill, Australia. ⁵Sir Charles Gairdner Hospital, Nedlands, Australia. ⁶Olivia Newton-John Cancer Research Institute, Heidelberg, Australia.

Published: 4 November 2015

References

1. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al: **Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.** *N Engl J Med* 2015, **372**:2006-2017.

¹Medical Oncology, Austin Health, Heidelberg, Australia
Full list of author information is available at the end of the article

- Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, *et al*: Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med* 2015, **373**:23-34.

doi:10.1186/2051-1426-3-S2-P126

Cite this article as: Prithviraj *et al.*: Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy. *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 2):P126.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

